Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
SINOPEC CORP
00386
5
CNOOC
00883
HK Stock MarketDetailed Quotes
MABPHARM-B (02181)
- 0.445
- -0.015-3.26%
Market Closed Apr 30 16:00 CST
1.84BMarket Cap29.67P/E (TTM)
0.465High0.445Low10.00KVolume0.445Open0.460Prev Close4.49KTurnover0.00%Turnover Ratio29.67P/E (Static)4.12BShares0.88052wk High10.60P/B1.84BFloat Cap0.40052wk Low--Dividend TTM4.12BShs Float1.800Historical High--Dividend LFY4.35%Range %0.250Historical Low0.449Avg Price2000Lot Size--Div Yield TTM--Div Yield LFY
MABPHARM-B (02181) Income Statement
All
YOY
| (FY)Dec 31, 2025 | (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 150.20%646.1M | 152.74%274.18M | 196.27%258.23M | 146.44%108.48M | 55.87%87.16M | 52.60%44.02M | -32.53%55.92M | -64.49%28.85M | --82.88M | --81.25M |
| Operating income | 150.20%646.1M | 152.74%274.18M | 196.27%258.23M | 146.44%108.48M | 55.87%87.16M | 52.60%44.02M | -32.53%55.92M | -64.49%28.85M | 82.88M | 81.25M |
| Cost of sales | -86.55%-72.44M | -133.16%-32.94M | -225.71%-38.83M | -127.93%-14.13M | 22.45%-11.92M | 43.93%-6.2M | 8.36%-15.38M | 34.08%-11.05M | ---16.78M | ---16.77M |
| Operating expenses | -86.55%-72.44M | -133.16%-32.94M | -225.71%-38.83M | -127.93%-14.13M | 22.45%-11.92M | 43.93%-6.2M | 8.36%-15.38M | 34.08%-11.05M | -16.78M | -16.77M |
| Gross profit | 161.47%573.65M | 155.68%241.25M | 191.60%219.39M | 149.47%94.36M | 85.58%75.24M | 112.57%37.82M | -38.67%40.54M | -72.40%17.79M | 66.11M | 64.48M |
| Selling expenses | -164.45%-400.82M | -134.55%-163.25M | -209.79%-151.57M | -157.35%-69.6M | -73.41%-48.93M | -77.18%-27.05M | -199.41%-28.21M | ---15.26M | ---9.42M | ---- |
| Administrative expenses | 0.03%-110.37M | 15.31%-51.37M | -5.49%-110.41M | -28.62%-60.65M | -15.57%-104.66M | 1.42%-47.15M | 0.08%-90.56M | -9.32%-47.83M | -37.75%-90.63M | -42.33%-43.76M |
| Research and development expenses | 23.51%-57.53M | 57.71%-23.81M | 38.96%-75.21M | 5.43%-56.29M | 16.70%-123.21M | 23.67%-59.53M | 43.88%-147.91M | 52.29%-77.99M | -118.88%-263.57M | -168.72%-163.46M |
| Impairment and provision | 93.35%-125K | 104.89%37K | -340.05%-1.88M | -18.31%-756K | -261.86%-427K | ---639K | ---118K | ---- | ---- | ---- |
| -Other impairment is provision | 93.35%-125K | 104.89%37K | -340.05%-1.88M | -18.31%-756K | -261.86%-427K | ---639K | ---118K | ---- | ---- | ---- |
| Special items of operating profit | 346.46%10.17M | 588.78%5.46M | 3.22%2.28M | -23.90%793K | -90.25%2.21M | -89.13%1.04M | 176.49%22.62M | 925.84%9.59M | 48.13%8.18M | -102.90%-1.16M |
| Operating profit | 112.75%14.97M | 109.03%8.32M | 41.24%-117.4M | 3.51%-92.15M | 1.89%-199.78M | 16.01%-95.5M | 29.62%-203.63M | 20.98%-113.71M | -60.13%-289.34M | -179.06%-143.89M |
| Financing cost | -2.44%-10.81M | -0.13%-5.43M | -10.17%-10.55M | -20.45%-5.42M | -33.25%-9.58M | -44.91%-4.5M | -199.13%-7.19M | -144.99%-3.1M | 39.04%-2.4M | 51.71%-1.27M |
| Earning before tax | 103.25%4.16M | 102.97%2.9M | 38.89%-127.95M | 2.43%-97.57M | 0.69%-209.36M | 14.39%-100M | 27.74%-210.82M | 19.53%-116.81M | -58.01%-291.74M | -167.88%-145.16M |
| Tax | --52.97M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| After-tax profit from continuing operations | 144.65%57.13M | 102.97%2.9M | 38.89%-127.95M | 2.43%-97.57M | 0.69%-209.36M | 14.39%-100M | 27.74%-210.82M | 19.53%-116.81M | -58.01%-291.74M | -167.88%-145.16M |
| Earning after tax | 144.65%57.13M | 102.97%2.9M | 38.89%-127.95M | 2.43%-97.57M | 0.69%-209.36M | 14.39%-100M | 27.74%-210.82M | 19.53%-116.81M | -58.01%-291.74M | -167.88%-145.16M |
| Profit attributable to shareholders | 144.65%57.13M | 102.97%2.9M | 38.89%-127.95M | 2.43%-97.57M | 0.69%-209.36M | 14.39%-100M | 27.74%-210.82M | 19.53%-116.81M | -58.01%-291.74M | -167.88%-145.16M |
| Basic earnings per share | 133.33%0.01 | 0 | 40.00%-0.03 | 0.00%-0.02 | 0.00%-0.05 | 33.33%-0.02 | 28.57%-0.05 | 25.00%-0.03 | -75.00%-0.07 | -300.00%-0.04 |
| Diluted earnings per share | 133.33%0.01 | 0 | 40.00%-0.03 | 0.00%-0.02 | 0.00%-0.05 | 33.33%-0.02 | 28.57%-0.05 | 25.00%-0.03 | -75.00%-0.07 | -300.00%-0.04 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
| Auditor | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome
牛牛課堂
Oct 13, 2025 18:05
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
Food流油
Apr 14, 2025 15:43
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"